Given the canonical CDKi function of p16 occurs in the nucleus, the prevalence of cytoplasmic staining in a variety of cancers raises questions regarding alternative non-canonical roles for p16, or how cancer cells may adapt alternative methods to enable progression through the cell cycle despite retaining a p16-positive status. Here, CDKN2A is linked to cancer.